# Shuttle Pharmaceuticals Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Shuttle Pharmaceuticals Holdings, Inc.). ## Overview Shuttle Pharmaceuticals Holdings, Inc. is a U.S.-based discovery and development stage pharmaceutical company focused on novel cancer therapies. The company’s work centers on product candidates designed to improve the effectiveness and delivery of radiation therapy and related oncology treatments. ## Products & services • Cancer therapy drug candidates • Radiation therapy sensitizers • Oncology pipeline development • Clinical trial and regulatory development • Proprietary cancer treatment technology - **Oncology drug candidates** (100%) — Investigational pharmaceutical products designed to treat cancer and improve standard therapies. - **Radiation therapy enhancement** (0%) — Compounds intended to improve the safety, reliability, or effectiveness of radiation treatment. - **Clinical development services** (0%) — Internal development activities supporting preclinical work, trials, and regulatory advancement. - Cancer therapy drug candidates - Radiation therapy sensitizers - Oncology pipeline development - Clinical trial and regulatory development - Proprietary cancer treatment technology ## Customers Shuttle Pharmaceuticals does not sell commercial products broadly; its primary stakeholders are oncology patients indirectly served through hospitals, cancer centers, and physicians if its candidates are approved. In the development stage, the company’s economic “customers” are effectively clinical investigators, research partners, regulators, and future healthcare providers that would adopt its therapies. - **Future oncology treatment providers** (primary) — Hospitals, cancer centers, and radiation oncology practices that would use approved therapies in patient care. - **Clinical trial ecosystem** (primary) — CROs, trial sites, investigators, and research partners supporting development of Ropidoxuridine and other candidates. - **Regulatory and scientific stakeholders** (secondary) — FDA and other oversight bodies, plus academic and clinical collaborators that influence approval and evidence generation. - Cancer centers and radiation oncologists, if products reach market - Hospitals and treatment networks seeking oncology therapies - Clinical trial sites that run studies for the pipeline - Regulators and research partners that shape development path - Future payers and providers that would reimburse approved therapies ## Geography The company is headquartered in the United States and conducts its development activities from a U.S. base. Its business is tied to U.S. clinical, regulatory, and financing markets, with no disclosed commercial revenue geography in the provided materials. - Headquartered in the United States - Clinical development and corporate functions are U.S.-based - Dependent on U.S. regulatory pathways for lead candidates - No country-level revenue disclosure in the provided reports - Exposure is concentrated in the U.S. biotech funding and trial ecosystem ## Strategy The company’s strategy is to advance a cancer-focused pipeline from discovery into clinical testing, with emphasis on therapies that complement radiation oncology. It also relies on external financing and third-party clinical infrastructure to support development, making capital access and trial execution central to its path forward. - **Advance Ropidoxuridine clinical trials** (short-term) — Clinical data is the main value driver for a development-stage oncology company. - **Maintain financing capacity** (short-term) — Development programs require ongoing external capital before product revenue exists. - **Position the platform around radiation oncology** (medium-term) — A focused therapeutic niche can differentiate the pipeline and support partnering. - Advance oncology candidates through clinical development - Focus on therapies that enhance radiation treatment - Use CROs and clinical sites to run trials efficiently - Preserve access to capital for development funding - Build evidence for future regulatory and commercial adoption ## Risks Shuttle Pharmaceuticals faces the typical risks of a pre-revenue biotech company: clinical failure, regulatory delays, and dependence on external funding. Because the business is centered on a small pipeline and third-party trial execution, setbacks in development or capital access can materially affect its ability to continue operations. - **Clinical development failure** [critical] — Pipeline value depends on trial results for Ropidoxuridine and related candidates. - **Funding and dilution risk** [high] — The company has no operating revenue and relies on equity or similar financing. - **Regulatory approval risk** [high] — Drug candidates must satisfy safety and efficacy requirements before commercialization. - **Third-party execution risk** [medium] — Trials depend on CROs, clinical sites, and vendors outside direct control. - No product revenue yet; value depends on successful development - Clinical trial outcomes may be negative or inconclusive - Regulatory approval is uncertain and time-consuming - Ongoing financing needs can dilute shareholders - Third-party CRO and site execution risk can delay programs ## Accounting The most important accounting judgments are tied to research and development expense, fair value estimates for convertible notes and warrants, and derivative financial instruments. Because the company is pre-revenue and financing-heavy, non-cash valuation changes and stock-based compensation can materially affect reported losses and period-to-period comparability. - **Research and development expense** — Higher trial activity increases reported R&D expense - **Fair value of convertible notes** — Can materially affect net loss and comparability - **Derivative financial instruments** — Can cause volatility in other expense - **Stock-based compensation** — Raises reported expenses without immediate cash outflow - R&D expense timing affects reported operating loss - Fair value of convertible notes can create non-cash gains/losses - Derivative liability remeasurement can swing other income/expense - Warrant valuation depends on assumptions and market inputs - Stock-based compensation affects cash burn vs reported expense --- *Last updated: 2026-04-29T04:58:26.737888+00:00*